Application of marker of proliferative activity Ki-67 for analysis of efficacy in complex treatment of patients, suffering locally-spread mammary gland cancer
Objective. Application of the proliferative activity marker Ki-67 for analysis of the results of neoadjuvant polychemotherapy, using regional or systemic ways of delivery of pharmacological preparations, for the patients, suffering locally spread mammary gland cancer (LS MGC).
Materials and methods. Retrospective analysis of the data, concerning 90 women-patients, suffering LS MGC, who obtained complex treatment, based on regional and systemic ways of the preparations administration.
Results. Dynamics of proliferative activity of a LS MGC as a result of neoadjuvant polychemotherapy, analyzed by the Ki-67 level determination, have demonstrated a statistically significant advantage of regional ways of the preparation injection, comparing with systemic ways of administration. Correlation of tumoral metastatic potential with level of Ki-67 was revealed, using detailed investigation.
Conclusion. It is possible to estimate tumoral proliferative activity and the neoadjuvant polychemotherapy efficacy, using Ki-67 analysis, and in such a way to select the optimal tactics of complex treatment.
Yamauchi H, Woodward WA, ValeroV, Alvarez RH, Lucci A, Buchholz TA, et al. Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist. 2012;17(7):891–9. doi: 10.1634/theoncologist.2012-0039.
Wirtz HS, Buist DSM, Gralow JR, Barlow WE, Gray Sh, Chubak J, et al. Frequent Antibiotic Use and Second Breast Cancer Events. Cancer Epidemiol Biomarkers Prev. 2013;22(9):1588–99. doi: 10.1158/1055-9965.EPI-13-0454.
Ording AG, Garne JP, Nyström PMW, Cronin-Fenton D, Tarp M, Sørensen HT, et al. Hospital Recorded Morbidity and Breast Cancer Incidence: A Nationwide Population-Based Case-Control Study. PLoS One. 2012;7(10):e47329. doi: 10.1371/journal.pone.0047329.
Landercasper J, Bailey L, Buras R, Clifford E, Degnim AC, Thanasoulis L, et al. The American Society of Breast Surgeons and Quality Payment Programs: Ranking, Defining, and Benchmarking More Than 1 Million Patient Quality Measure Encounters Ann Surg Oncol. 2017;24(10):3093–106. doi: 10.1245/s10434-017-5940-1.
Greenlee H, DuPont-Reyes MJ, BalneavesLG, Carlson LE, Cohen MR, Deng G, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and following breast cancer treatment. CA Cancer J Clin. May 2017;67(3):194–232. https://doi.org/10.3322/caac.21397.
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97. doi: 10.3322/caac.21405.
Sueishi M, Takagi M, Yoneda Y. The forkhead-associated domain of Ki-67 antigen interacts with the novel kinesin-like protein Hklp2. J Biol Chem. 2000; 275:28888-92. doi: 10.1074/jbc.M003879200.
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20. doi: 10.1002/ijc.2910310104.
Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2009;100(3): 207–12. doi: 10.1093/jnci/djm289.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncology. 2010;11(2):174–83.
This work is licensed under a Creative Commons Attribution 4.0 International License.